**Supplemental Data**

**Table S1:** Analysis of Solid-Organ Transplant Patients With and Without EIA-Positive *Clostridioides difficile* infection

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | Non-CDI Patients(n=337, 98.3%) | CDI Patients(n=6, 1.7%) | Bivariate | Multivariate |
| OR (95% CI) | OR (95% CI) |
| *C. difficile* colonization, no. (%)\_ | 27 (8.0) | 3 (50.0) | 11.48 (2.21–59.66)b | 12.62 (2.31–69.01)b |
| Age, mean y ± SDa | 56.76 ± 13.18 | 66.99 ± | 1.08 (1.00–1.16) | 1.09 (1.00–1.18) |
| Female gender, no. (%) | 147 (43.6) | 3 (50.0) | 1.29 (0.26–6.50) | … |
| **Race, no. (%)** |  |  |  |  |
|  White | 217 (64.4) | 5 (83.3) | Reference | … |
|  Other | 120 (35.6) | 1 (16.7) | 0.36 (0.04–3.13) | … |
| **SOT type, no. (%)** |  |  |  |  |
|  Kidney | 197 (58.5) | 3 (50.0) | Reference |  |
|  Liver | 69 (20.5) | 2 (33.3) | 1.90 (0.31–11.63) | … |
|  Other | 71 (21.0) | 1 (16.7) | 0.92 (0.09–9.04) | … |
| Months since transplant, mean y ± SDc  | 112.8±107.9 | 147.0 | 1.00 (1.00–1.01) | … |
| **Antibiotics, no. (%)d** |  |  |  |  |
|  Any antibiotic  | 288 (85.5) | 6 (100.0) |  |  |
|  Penicillins | 123 (36.5) | 3 (50.0) | 1.74 (0.35–8.75) | … |
|  Cephalosporins | 238 (70.6) | 5 (83.3) | 2.08 (0.24–18.03) | … |
|  Carbapenems  | 42 (12.5) | 1 (16.7) | 1.40 (0.16–12.32) | … |
|  Fluoroquinolones | 117 (34.7) | 3 (50.0) | 1.88 (0.37–9.46) | … |
|  Vancomycin | 122 (36.2) | 3 (50.0) | 1.76 (0.35–8.87) | … |
|  Linezolid | 62 (18.4) | 1 (16.7) | 0.89 (0.10–7.73) | … |
|  Clindamycin | 30 (8.9) | 2 (33.3) | 5.12 (0.90–29.10) | … |
|  Macrolides | 59 (17.5) | 2 (33.3) | 2.36 (0.42–13.16) | … |
|  TMP/SMX | 143 (42.4) | 2 (33.3) | 0.68 (0.12–3.75) | … |
|  Othere | 81 (24.0) | 0 (0.0) |  | … |
| **Acid suppressants, no. (%)d** |  |  |  |  |
|  Any acid suppressant  | 273 (81.0) | 5 (83.3) |  | … |
|  PPIs  | 173 (51.3) | 4 (66.7) | 1.90 (0.34–10.49) | … |
|  H2 blockers | 159 (47.2) | 3 (50.0) | 1.12 (0.22–5.63) | … |
| **Immunosuppressants, no. (%)d** |  |  |  |  |
|  Any immunosuppressant  | 313 (92.9) | 6 (100.0) |  |  |
|  Prednisone | 195 (57.9) | 4 (66.7) | 1.46 (0.26–8.06) | … |
|  Tacrolimus | 235 (69.7) | 3 (50.0) | 0.43 (0.09–2.19) | … |
|  Azathioprine | 25 (7.4) | 0 (0.0) |  |  |
|  Cyclosporine  | 34 (10.1) | 2 (33.3) | 4.46 (0.79–25.24) | … |
|  Mycophenolate  | 211 (62.6) | 3 (50.0) | 0.60 (0.12–3.00) | … |
| **Hospitalization, no. (%)d** |  |  |  |  |
|  No. of hospitalizations, mean ± SDf | 2.53±2.22 | 3.00±1.41 | 1.08 (0.80–1.45) | … |
|  No. of hospital days, mean ± SDg | 14.14±15.45 | 20.08±9.19 | 1.02 (0.98–1.06) | … |

Note. CDI, *Clostridioides difficile* infection; OR, odds ratio; CI, confidence interval; SD, standard deviation; SOT, solid-organ transplant; TMP/SMX, trimethoprim/sulfamethoxazole; PPI, proton pump inhibitor; H2 blocker, histamine 2 receptor blocker.

aOdds ratio calculated for 1-year increase in age.

bDenotes a *P* value <.05.

cMeasured as months from SOT to last colonization test.

dAssessed from first screening test to CDI, death or loss to follow-up.

eIncludes aztreonam, dapsone, daptomycin, metronidazole, rifaximin and tetracyclines.

fOdds ratio calculated for 1 additional hospitalization.

gOdds ratio calculated for 1 additional hospital day.